Navigation Links
Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

BASKING RIDGE, N.J., Jan. 6 /PRNewswire/ -- Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, the REG1 System, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
2. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
3. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
4. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
5. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
6. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
8. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
9. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
10. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
11. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will feature ... Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ... how to continue to feed a growing nation. At the same time, many of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):